catalog number :
MBS9126724
products full name :
Phospho-CDK4-T172
products short name :
CDK4-T172
other names :
Cyclin-dependent kinase 4; Cyclin-dependent kinase 4; cyclin-dependent kinase 4; cell division protein kinase 4; cyclin-dependent kinase 4; Cell division protein kinase 4; PSK-J3
products gene name :
CDK4
other gene names :
CDK4; CDK4; CMM3; PSK-J3
uniprot entry name :
CDK4_HUMAN
reactivity :
Human, Mouse, Rat
purity :
Affinity purification
storage stability :
Store at -20 degre C (regular) or -80 degre C (long term). Avoid freeze / thaw cycles.
tested application :
Western Blot (WB)
app notes :
WB: 1:500-1:2000
other info1 :
Antibody Type: Primary antibody. Species: Human. Route: Synthetic Peptide. Immunogen: A phospho specific peptide corresponding to residues surrounding T172 of human CDK4
other info2 :
Swiss Prot: P11802. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
products categories :
Phosphorylation
ncbi pathways :
ATF-2 Transcription Factor Network Pathway (138006); B Cell Receptor Signaling Pathway (198909); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Calcineurin-regulated NFAT-dependent Transcription In Lymphocytes Pathway (137993); Cell Cycle Pathway (530733); Cell Cycle, Mitotic Pathway (105765); Cell Cycle Pathway (198811); Cell Cycle Pathway (83054); Cell Cycle Pathway (463)
ncbi summary :
The protein encoded by this gene is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16(INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. [provided by RefSeq, Jul 2008]
uniprot summary :
CDK4: a protein kinase of the CDK family that is important for cell cycle G1 phase progression. Its activity is restricted to the G1-S phase. Controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16(INK4a). Phosphorylates the retinoblastoma gene product (Rb). Point mutations found in somatic and familial melanoma. Amplified in sarcomas, glioma and lymphoma. Amplified, methylated or deleted in head and neck squamous cell carcinoma. Overexpression drives epithelial tumors in mice. Disruption makes mice resistant to cancer. Inhibitor: PD332991. Protein type: EC 2.7.11.22; Kinase, protein; Protein kinase, CMGC; Cell cycle regulation; Protein kinase, Ser/Thr (non-receptor); CMGC group; CDK family; CDK4 subfamily; CDK/CDK4 subfamily. Chromosomal Location of Human Ortholog: 12q14. Cellular Component: nucleoplasm; transcription factor complex; nuclear membrane; tight junction; perinuclear region of cytoplasm; nucleolus; cyclin-dependent protein kinase holoenzyme complex; nucleus; chromatin; cytosol. Molecular Function: protein binding; cyclin binding; cyclin-dependent protein kinase activity; protein complex binding; cyclin-dependent protein kinase regulator activity; ATP binding. Biological Process: circadian rhythm; lens development in camera-type eye; response to drug; establishment and/or maintenance of chromatin architecture; organ regeneration; positive regulation of cell size; positive regulation of translation; positive regulation of apoptosis; response to toxin; response to testosterone stimulus; signal transduction; protein amino acid phosphorylation; positive regulation of fibroblast proliferation; response to hyperoxia; regulation of gene expression; cell division; response to lead ion; positive regulation of cell proliferation; mitotic cell cycle; regulation of protein kinase activity; G1/S transition of mitotic cell cycle. Disease: Melanoma, Cutaneous Malignant, Susceptibility To, 3